German biotech CureVac has started a Phase 2b/3 clinical trial of its Covid-19 vaccine candidate CVnCoV. Planned to enroll 36,500 participants in Europe and Latin America...
Germany’s Wacker Chemie has signed a contract to manufacture the active substance for compatriot CureVac’s Covid-19 vaccine candidate CVnCoV. Under the terms, the biotech...
German biotech CureVac has signed a supply agreement with the European Commission to provide an initial 225 million doses of its mRNA-based Covid-19 vaccine, with an...
After months of uncertainty and anxious glances across the water as potential Covid-19 vaccine manufacturers made deal after deal with other political blocs, the EU over...
German biotech CureVac has more than tripled its market value to over $5 billion in an initial public offering launched on the US Nasdaq Global Market. Altogether 13.33...
The European Investment Bank (EIB) has granted German biotech CureVac a €75 million loan to support its ongoing development of vaccines against infectious diseases...
17.06.2020
- The German federal government is taking a 23.1% stake, worth €300 million, in privately owned biotech CureVac. It’s an unusual move for Berlin, but economics minister Peter...
17.03.2020
- News reports that the US government had offered considerable sums of money to lure top-level scientists working for a Germany-based privately owned biotech, or even the company...
